MarketOpen Podcast Episode 169 - Eve Health Group

This episode features Ben Rohr, CEO of EVE Health, discussing the company's reformulation platform, flagship product Libbo, and its approach to developing differentiated pharmaceutical products. The conversation explores the market opportunity in erectile dysfunction treatments, Libbo’s role as a proof point for the platform, the impact of the pharmaceutical patent cliff, EVE Health’s broader growth strategy, global market opportunities, and the key milestones investors can expect as the company continues to commercialise its portfolio.